LinkedIn Profile

Access Principia Biopharma historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:prnb 2054560 May 5th, 2024 12:00AM Principia Biopharma 4.7K 17.00 Open May 5th, 2024 12:01AM May 5th, 2024 12:01AM We are a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Our proprietary Tailored Covalency® platform enables us to design and develop reversible and irreversible covalent small molecule inhibitors with potencies and selectivities that we believe will rival those of injectable biologics, yet maintain the convenience of a pill. Our strategy is to advance the development of our proprietary drug candidates, and for certain programs, use collaborations and partnerships as strategic tools to maximize the value of those assets. Open Open 220 E Grand Ave South San Francisco California US 94080 Principia Biopharma
nasdaq:prnb 2054560 May 4th, 2024 12:00AM Principia Biopharma 4.7K 17.00 Open May 3rd, 2024 11:35PM May 4th, 2024 07:14PM We are a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Our proprietary Tailored Covalency® platform enables us to design and develop reversible and irreversible covalent small molecule inhibitors with potencies and selectivities that we believe will rival those of injectable biologics, yet maintain the convenience of a pill. Our strategy is to advance the development of our proprietary drug candidates, and for certain programs, use collaborations and partnerships as strategic tools to maximize the value of those assets. Open Open 220 E Grand Ave South San Francisco California US 94080 Principia Biopharma
nasdaq:prnb 2054560 May 3rd, 2024 12:00AM Principia Biopharma 4.7K 17.00 Open May 2nd, 2024 11:31PM May 3rd, 2024 03:00PM We are a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Our proprietary Tailored Covalency® platform enables us to design and develop reversible and irreversible covalent small molecule inhibitors with potencies and selectivities that we believe will rival those of injectable biologics, yet maintain the convenience of a pill. Our strategy is to advance the development of our proprietary drug candidates, and for certain programs, use collaborations and partnerships as strategic tools to maximize the value of those assets. Open Open 220 E Grand Ave South San Francisco California US 94080 Principia Biopharma
nasdaq:prnb 2054560 May 2nd, 2024 12:00AM Principia Biopharma 4.7K 17.00 Open May 1st, 2024 11:39PM May 2nd, 2024 10:39AM We are a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Our proprietary Tailored Covalency® platform enables us to design and develop reversible and irreversible covalent small molecule inhibitors with potencies and selectivities that we believe will rival those of injectable biologics, yet maintain the convenience of a pill. Our strategy is to advance the development of our proprietary drug candidates, and for certain programs, use collaborations and partnerships as strategic tools to maximize the value of those assets. Open Open 220 E Grand Ave South San Francisco California US 94080 Principia Biopharma
nasdaq:prnb 2054560 May 1st, 2024 12:00AM Principia Biopharma 4.7K 17.00 Open May 1st, 2024 01:29AM May 1st, 2024 10:03AM We are a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Our proprietary Tailored Covalency® platform enables us to design and develop reversible and irreversible covalent small molecule inhibitors with potencies and selectivities that we believe will rival those of injectable biologics, yet maintain the convenience of a pill. Our strategy is to advance the development of our proprietary drug candidates, and for certain programs, use collaborations and partnerships as strategic tools to maximize the value of those assets. Open Open 220 E Grand Ave South San Francisco California US 94080 Principia Biopharma
nasdaq:prnb 2054560 Apr 30th, 2024 12:00AM Principia Biopharma 4.7K 17.00 Open Apr 29th, 2024 11:58PM Apr 30th, 2024 08:57AM We are a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Our proprietary Tailored Covalency® platform enables us to design and develop reversible and irreversible covalent small molecule inhibitors with potencies and selectivities that we believe will rival those of injectable biologics, yet maintain the convenience of a pill. Our strategy is to advance the development of our proprietary drug candidates, and for certain programs, use collaborations and partnerships as strategic tools to maximize the value of those assets. Open Open 220 E Grand Ave South San Francisco California US 94080 Principia Biopharma
nasdaq:prnb 2054560 Apr 29th, 2024 12:00AM Principia Biopharma 4.7K 17.00 Open Apr 29th, 2024 02:36AM Apr 29th, 2024 10:04AM We are a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Our proprietary Tailored Covalency® platform enables us to design and develop reversible and irreversible covalent small molecule inhibitors with potencies and selectivities that we believe will rival those of injectable biologics, yet maintain the convenience of a pill. Our strategy is to advance the development of our proprietary drug candidates, and for certain programs, use collaborations and partnerships as strategic tools to maximize the value of those assets. Open Open 220 E Grand Ave South San Francisco California US 94080 Principia Biopharma
nasdaq:prnb 2054560 Apr 28th, 2024 12:00AM Principia Biopharma 4.7K 17.00 Open Apr 27th, 2024 11:52PM Apr 27th, 2024 11:52PM We are a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Our proprietary Tailored Covalency® platform enables us to design and develop reversible and irreversible covalent small molecule inhibitors with potencies and selectivities that we believe will rival those of injectable biologics, yet maintain the convenience of a pill. Our strategy is to advance the development of our proprietary drug candidates, and for certain programs, use collaborations and partnerships as strategic tools to maximize the value of those assets. Open Open 220 E Grand Ave South San Francisco California US 94080 Principia Biopharma
nasdaq:prnb 2054560 Apr 27th, 2024 12:00AM Principia Biopharma 4.7K 17.00 Open Apr 26th, 2024 11:32PM Apr 26th, 2024 11:32PM We are a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Our proprietary Tailored Covalency® platform enables us to design and develop reversible and irreversible covalent small molecule inhibitors with potencies and selectivities that we believe will rival those of injectable biologics, yet maintain the convenience of a pill. Our strategy is to advance the development of our proprietary drug candidates, and for certain programs, use collaborations and partnerships as strategic tools to maximize the value of those assets. Open Open 220 E Grand Ave South San Francisco California US 94080 Principia Biopharma
nasdaq:prnb 2054560 Apr 26th, 2024 12:00AM Principia Biopharma 4.7K 17.00 Open Apr 25th, 2024 11:39PM Apr 26th, 2024 09:00AM We are a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Our proprietary Tailored Covalency® platform enables us to design and develop reversible and irreversible covalent small molecule inhibitors with potencies and selectivities that we believe will rival those of injectable biologics, yet maintain the convenience of a pill. Our strategy is to advance the development of our proprietary drug candidates, and for certain programs, use collaborations and partnerships as strategic tools to maximize the value of those assets. Open Open 220 E Grand Ave South San Francisco California US 94080 Principia Biopharma

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.